Acetylcystein is a potent antioxidans which is able to prevent contrast dye induced nephropathy in stable patients undergoing additional hydration. In primary percutaneous intervention for infarction hydration is not possible. Therefore Acetylcystein might prevent contrast dye induced nephropathy. Furthermore, it might reduce infarct size as a result of its antioxidant properties. Clinical trials are missing so far examining the effects of Acetylcystein on nephropathy and infarct size.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
251
high-dose N-Acetylcystein during PCI and for 2/day for 2 days
NaCl as placebo
University of Leipzig - Heart Center
Leipzig, Germany
Myocardial salvage measured by magnetic resonance imaging
Time frame: 4 days
prevention of nephropathy
Time frame: 3 days
ST-segment resolution
Time frame: 90 min
TIMI flow
Time frame: minutes
composite clinical endpoint (death, reinfarction, congestive heart failure)
Time frame: 30 days
need for dialysis
Time frame: 4 days
microvascular obstruction measured by magnetic resonance
Time frame: 4 days
infarct size measured by magnetic resonance
Time frame: 4 days
oxidative stress
Time frame: 72 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.